Medications

US approves highly anticipated Eli Lilly weight loss drug

The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful—and lucrative—new obesity medicines.

Inflammatory disorders

A promising target to fight inflammatory bowel diseases

Inflammatory bowel diseases (IBDs), such as Crohn's disease or ulcerative colitis, arise when there is a dysregulation of the cell signaling pathways controlling the maintenance of homeostasis in the gut, leading to a chronic ...

page 11 from 40